Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Moser

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Cell|June 2, 2023
Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticityMansi Arora, Justin Moser, Timothy E Hoffman, et al.
Pigment Cell & Melanoma Research|May 23, 2025
Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous MelanomaStephanie J Wang, Joanne Xiu, Katherine M Butcher, et al.
Cancers|March 25, 2022
Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene FusionsSourat Darabi, Andrew Elliott, David R Braxton, et al.
Journal for Immunotherapy of Cancer|August 3, 2024
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, et al.
Pigment Cell & Melanoma Research|October 10, 2024
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023Rino S Seedor, Andrew E Aplin, Corine Bertolotto, et al.
Oncoimmunology|July 6, 2026
Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platformTithi Ghosh Halder, Erin Kelley, Jorge Soria-Bustos, et al.
Journal for Immunotherapy of Cancer|December 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancerRebecca Porter, Bruno Bockorny, Bradley R Corr, et al.
The British Journal of Dermatology|October 22, 2024
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanomaErin McGillivray, Karam Ashouri, Eftychia Chatziioannou, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cell|June 2, 2023
Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticityMansi Arora, Justin Moser, Timothy E Hoffman, et al.
Pigment Cell & Melanoma Research|May 23, 2025
Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous MelanomaStephanie J Wang, Joanne Xiu, Katherine M Butcher, et al.
Cancers|March 25, 2022
Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene FusionsSourat Darabi, Andrew Elliott, David R Braxton, et al.
Journal for Immunotherapy of Cancer|August 3, 2024
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, et al.
Pigment Cell & Melanoma Research|October 10, 2024
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023Rino S Seedor, Andrew E Aplin, Corine Bertolotto, et al.
Oncoimmunology|July 6, 2026
Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platformTithi Ghosh Halder, Erin Kelley, Jorge Soria-Bustos, et al.
Journal for Immunotherapy of Cancer|December 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancerRebecca Porter, Bruno Bockorny, Bradley R Corr, et al.
The British Journal of Dermatology|October 22, 2024
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanomaErin McGillivray, Karam Ashouri, Eftychia Chatziioannou, et al.
Pageof 3